naltrexone has been researched along with moxifloxacin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andersen, MP; Graff, C; Højer, AM; Kallio, A; Kanters, JK; Matz, J; Struijk, JJ; Toft, E; Vainio, PJ | 1 |
| Bhuiyan, TA; Graff, C; Kanters, JK; Matz, J; Melgaard, J; Nielsen, J; Struijk, JJ; Toft, E | 1 |
| Bai, SA; Darpo, B; Ferber, G; Finn, A; Xiang, Q; Zhou, M | 1 |
| Colucci, S; Harris, SC; Morganroth, J; Ripa, SR; Thorn, MD | 1 |
| Brown, R; Darpo, B; McDonnell, D; Nangia, N; Rege, B; Sun, L; von Moltke, L; Xue, H; Yagoda, S | 1 |
1 review(s) available for naltrexone and moxifloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for naltrexone and moxifloxacin
| Article | Year |
|---|---|
Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Topics: Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Biomarkers, Pharmacological; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Guidelines as Topic; Heart Rate; Humans; Long QT Syndrome; Male; Moxifloxacin; Naltrexone; Narcotic Antagonists; Placebos; Prospective Studies; Quinolines; Treatment Outcome; Young Adult | 2011 |
Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.
Topics: Adult; Buprenorphine; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart; Heart Rate; Humans; Male; Moxifloxacin; Naltrexone | 2016 |
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Topics: Administration, Cutaneous; Adult; Arrhythmias, Cardiac; Aza Compounds; Buprenorphine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoroquinolones; Healthy Volunteers; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Naltrexone; Pain; United States; Young Adult | 2017 |
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia | 2020 |
6 other study(ies) available for naltrexone and moxifloxacin
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The T-peak-T-end interval as a marker of repolarization abnormality: a comparison with the QT interval for five different drugs.
Topics: Adult; Biomarkers; Clinical Trials as Topic; Dihydropyridines; Electrocardiography; Female; Fluoroquinolones; Humans; Imidazoles; Indoles; Male; Moxifloxacin; Naltrexone; Pharmaceutical Preparations; Sotalol | 2015 |